Catalyst Pharmaceuticals, Inc. (CPRX)
| Market Cap | 357.59M |
| Revenue (ttm) | 118.18M |
| Net Income (ttm) | 71.48M |
| Shares Out | 103.54M |
| EPS (ttm) | 0.67 |
| PE Ratio | 5.27 |
| Forward PE | 11.11 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $3.53 |
| Previous Close | $3.50 |
| Change ($) | 0.03 |
| Change (%) | 0.86% |
| Day's Open | 3.52 |
| Day's Range | 3.27 - 3.56 |
| Day's Volume | 1,699,483 |
| 52-Week Range | 2.55 - 5.19 |
CORAL GABLES, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commerci...
CORAL GABLES, Fla., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercia...
Penny stocks are low price for a reason. Most presume they're destined for bankruptcy.
Now that AMC, GameStop, American Airlines and Bed, Bath & Beyond have been pushed to wild levels, well above any sane valuation, the question is which companies will be the next to be “recomme...
Investors can start the new year off right by digging into these three small but fiery stocks.
Catalyst (CPRX) plans to expand its product portfolio beyond Firdapse.
Investors focused on assets with high returns may want to consider the following non-cyclical stocks, as their earnings yields (as calculated through Joel Greenblatt's method) are outperformin...
CORAL GABLES, Fla., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercia...
Catalyst Pharma is a commercial-stage small biotech with a highly profitable orphan drug Firdapse for adult LEMS patients in the US market. Catalyst Pharma is trading at PE ratio of 5 and pric...
Three referenced quant rating categories (value, growth, and profitability) are significant considerations in selecting healthcare investments. The data underlying the value, growth, and profi...
Catalyst Pharmaceuticals (CPRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
These are the biotech stocks with the best value, fastest growth, and most momentum for Q1 2021.
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q3 2020 Results - Earnings Call Transcript
Catalyst (CPRX) beats on earnings but misses sales estimates in the third quarter of 2020.
Catalyst (CPRX) delivered earnings and revenue surprises of 22.22% and -6.10%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update
- Firdapse® Third Quarter Net Revenues of $ 29. 2 Million
Catalyst (CPRX) will provide updates on earnings and revenues when its releases third-quarter 2020 results.
Catalyst Pharmaceuticals stock has been on a wild ride since its drug got FDA approval -- and despite legal drama, it may be worth the risk. The post Despite Legal Drama, Catalyst Pharmaceutic...
CORAL GABLES, Fla., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercia...
As markets continue sliding on economic recovery slowdown fears, five Ben Graham Lost Formula stocks with high financial strength are Sabine Royalty Trust (NYSE:SBR), XBiotech Inc. (NASDAQ:XBI...
Typically, a major clinical victory would boost names like Catalyst Pharmaceuticals stock. Unfortunately, some political rumblings and an unexpected competitor got in the way of CPRX.
CORAL GABLES, Fla., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercia...
Catalyst Pharmaceuticals Has Potential To Push Higher If They Can Overcome Current Headwinds
Issued Patent is the First Covering Firdapse® Issued Patent is the First Covering Firdapse®
CORAL GABLES, Fla., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today reported that the federal judge handling Catalyst's case against the FD...
Investors often get excited about small-cap biotech and emerging pharmaceutical stocks because the upside can be exponential if their drugs and treatments become a hit.
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Catalyst can't seem to catch a break in the clinic these days.
Catalyst's (CPRX) efforts to expand Firdapse label are encouraging. However, with only a few candidates in the pipeline, the company's dependence on Firdapse for growth remains a matter of con...
Notice of Application for Judicial Review Filed Today in the Federal Court of Canada Notice of Application for Judicial Review Filed Today in the Federal Court of Canada
CORAL GABLES, Fla., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commerc...
Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q2 2020 Results - Earnings Call Transcript
Firdapse fails to hit the mark in the clinic yet again.
Catalyst (CPRX) beats both earnings and sales estimates in the second quarter of 2020.
-The allowed claims are directed to methods of treating patients with a 3,4-DAP sensitive disease comprising administering 3,4-DAP or a salt thereof to slow acetylating patients having certain...
Catalyst (CPRX) delivered earnings and revenue surprises of 12.50% and 2.20%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- Firdapse® Second Quarter Net Revenues of $29.6 Million
Catalyst Pharmaceuticals (NASDAQ: CPRX) announces its next round of earnings this Monday, August 10.
CORAL GABLES, Fla., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commerc...
CORAL GABLES, Fla., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commerc...
CORAL GABLES, Fla., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commerc...
CORAL GABLES, Fla., July 31, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today reported that the Magistrate Judge considering Catalyst's lawsuit agains...
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New York, New York--(Newsfile Corp. - July 16, 2020) - Levi & Korsinsky announces it has commenced an investigation of Catalyst Pharmaceuticals, Inc.
As the market continues to grapple with the effects of the coronavirus pandemic, some investors are seeing strength among U.S.
-Pete Curry has been Promoted to Vice President of Sales
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q1 2020 Results - Earnings Call Transcript
Catalyst (CPRX) beats on Q1 earnings but misses on revenues. It also withdraws sales guidance due to the coronavirus pandemic.
About CPRX
Catalyst Pharmaceuticals, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal musc... [Read more...]
| Industry Biotechnology | IPO Date Nov 8, 2006 |
| CEO Patrick McEnany | Employees 76 |
| Stock Exchange NASDAQ | Ticker Symbol CPRX |
Analyst Forecasts
According to 5 analysts, the average rating for CPRX stock is "Buy." The 12-month stock price forecast is 7.40, which is an increase of 109.63% from the latest price.